Fig. 5. PARP14 restricts the replication of HSV-1 in A549 cells.
A) WT and PARP14 KO A549 cells were infected with HSV-1 at an MOI of 0.01 PFU/cell. Cells and supernatants were collected at indicated time points and progeny virus was quantified by plaque assay. B) WT and PARP14 KO A549 cells were infected with HSV-1 at an MOI of 0.1. At 24 hpi RNA was harvested from infected cells and HSV-1 immediate early gene ICP4, ICP0 and ICP27 mRNAs were quantified by qPCR using ΔCt method having 18S rRNA abundance as the endogenous control. The data in A-B is from 1 experiment representative of 2 independent experiments. N=3 per group. C) WT and PARP14 KO A549 cells were infected with serial dilutions of HSV-1 starting at a concentration of 1.85×109 PFU/ml and plaquing efficiency was determined at 24 hpi. This data is the combined results of 3 separate experiments, N=9 per group. D) WT A549 cells were infected with HSV-1 at an MOI of 0.1 PFU/cell and then treated with DMSO or PARP14i (1 μM) at 1 hpi. Cells and supernatants were collected at 24 hpi and progeny virus was quantified by plaque assay. The data in D is from 1 experiment representative of 2 independent experiments. N=3 per group.